Announcements
Current & archive
Horizon Scanning in Onkology - Reports
We are pleased to introduce two new HSO reports.
DSD HSO No. 47
Ibrutinib (Imbruvica®) for relapsed or refractory chronic lymphocytic leukaemia
DSD HSO No. 48
Bevacizumab (Avastin®) for platinum-resistant recurrent, epithelial ovarian, fallopian tube or primary peritoneal cancer
Assessment – APPRAISAL – Decision: (Good) Practice examples and recommendations
Health Technology Assessment HTA has in many countries become an integral part of health policy decision-making. After the assessment (the synthesis of available research evidence) some countries undertake an appraisal of the evidence’s impact and applicability for a specific context. Appraisal committees, sometimes called policy committees, work where research and policy meet. Appraisal committees facilitate the life of decision makers in health policy by translating research results into political recommendations. This working paper presents 11 appraisal committees from 7 countries and condenses their experience into recommendations. An appraisal committee set up in line with these examples of good-practice may serve as an important building block for transparent and evidence-based decision making in health policy.
Publication: Decision Support Document Nr. 72: https://eprints.aihta.at/1036
Contact: Claudia Wild
Costs of day surgery in Austria: An analysis of data and methods for varicose vein surgery as an example
The report contains an analysis of data and methods to calculate the costs of day surgery and inpatient treatment in Austria. Thus, varicose vein surgery was chosen as an example to proof several data sources for their applicability. Beside the calculation by using Austrian meta data and international costs from the UK, we used costs from individual hospitals. The calculated costs differed between 859 and 4,664 Euros for day surgery and 1,720-2,330 Euros for an inpatient treatment.
Publication: LBI-HTA Project report No. 71: https://eprints.aihta.at/1035
Contact: Stefan Fischer
Horizon Scanning in Onkology - Reports
We are pleased to introduce our new HSO report.
DSD HSO No. 46
Bevacizumab (Avastin®) as maintenance therapy after first progression on bevacizumab for patients with advanced colorectal carcinoma
New HTA-teaching and practice book
The new HTA-teaching and practice book (revised 2nd edition) has been released.
With the collaboration of C. Wild and I. Zechmeister-Koss.
Horizon Scanning in Oncology – Prioritisation of new and emerging oncologic drugs
Within the project Horizon Scanning in Oncology 9 databases are frequently scanned to identify new/emerging oncologic drugs. Every 3 months, these drugs are filtered according to predefined criteria (i.e. in most instances availability of phase III study results) and are then prioritised by an expert panel to identify those therapies for which either a substantial clinical or financial impact can be expected.
Evaluation of individual medical procedures 2014 - Reports
We are pleased to introduce our new reports.
Decision Support Documents 2014:
-
DSD 74: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of peritoneal carcinomatosis
https://eprints.aihta.at/1031 -
DSD 75: Drug eluting stents for the treatment of peripheral artery disease
https://eprints.aihta.at/1032 -
DSD 76: Stereotactic Radiofrequency ablation/ SRFA for hepatocellular carcinoma and liver metastases
https://eprints.aihta.at/1030
+2 Updates:
-
DSD 20/ Update 2014: Implantation of endobronchial valves in patients with emphysema
https://eprints.aihta.at/1028 -
DSD 44/1. Update 2014: Percutaneous left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation (1st Update 2014)
https://eprints.aihta.at/1029
Horizon Scanning in Onkology - Reports
We are pleased to introduce our new HSO report.
DSD HSO No. 45
Obinutuzumab (Gazyva®) for previously untreated patients with chronic lymphocytic leukaemia (CLL)
Sustainability of inpatient psychiatric rehabilitation for adults: systematic review
Against the backdrop of an increase in disability pensions due to mental health disorders, the aim of this review was a systematic analysis of the sustainability of inpatient psychiatric/ psychosomatic rehabilitation covering an observation period of at least 12 months after discharge from rehabilitation.
Overall, included studies (1 meta-analysis, 4 RCTs, 2 pre-post studies with, and 14 without a control group) showed similar trends: the improvement between admission and discharge deteriorated to varying degrees during the catamnestic period. Nevertheless, results remained better than at admission, though. In studies on specific aftercare we observed a trend towards an improved stabilization of treatment effects.
Publication: LBI-HTA Project report No.75: https://eprints.aihta.at/1025
Contact: Brigitte Piso
Horizon Scanning in Onkology - Reports
We are pleased to introduce our new HSO report.